Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2018 · 10-Q
Revenue$611.00K$611.00K+0.2% vs Q1 2017 Net Income-$2.53M-$2.53MN/M vs Q1 2017 EPS Diluted$0.18$0.18−10.0% vs Q1 2017 Operating Income-$2,732,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Margins · derivedOperating margin-447.1%−54.0 pt vs Q1 2017
Net margin-414.2%+17.9 pt vs Q1 2017
ended Nov 30, 2017 · filed Jan 11, 2018 · 42 d after period end